Back to News
Market Impact: 0.5
Ionis' Zanvastro Wins FDA Approval For Alexander Disease, Set For U.S. Launch
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Ionis Pharmaceuticals announced U.S. FDA approval of Zanvastro (Zanvastro) for the treatment of Alexander disease in both pediatric and adult patients. This approval is a major regulatory milestone for the company’s RNA-targeted therapeutics pipeline and should be supportive for expectations around future revenue contributions.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
IONS0.85
More News
- Indonesian stocks plunge to six-year low as MSCI downgrade fears mount
- China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround
- Australia’s Cleanaway agrees to $6.5 bln EQT buyout bid; shares surge
- India’s Finance Minister blames easy exits and excess liquidity for equity market's underperformance
- Daiichi Life Offers to Buy Remainder of Australia’s Challenger
- 'MASSIVE ECONOMIC DAMAGE': 17 States FIGHT Wall Street's ESG standards